ImmunityBio converts from Immunomedics Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ImmunityBio converts from Immunomedics

IBRX 2.139

+0.9%

Nov 7 9:30 AM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

Recommended by:

To: urslor who wrote (936)	3/29/2025 3:57:56 PM
From: bobbseytwins2001	8 Recommendations of 1229

Seems to us like the "challenge" of holding or buying more IBRX is really the difference between short term trading or long term investing. The fact that Anktiva is now an FDA approved product for bladder cancer with sales ramping up tells us from experience that the fundamental value of the company will grow. If eventually other cancers are treatable with Anktiva, and if it is approved for some of them, sales will continue to grow. This is the definition of investing for the long term. If investors own IBRX for a trade, the fact that the entire Biotech community is in a long term consolidation [bear market] with no end in sight makes it look silly. As an investment IBRX is in position to become cash flow positive within a year or so, and that is a whole new ballgame. Of course an international partnership with capital investment is the wild card.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next